Tuomas P Kilpeläinen1, Dimitri Pogodin-Hannolainen2, Kimmo Kemppainen3, Kirsi Talala4, Jani Raitanen5, Kimmo Taari6, Paula Kujala7, Teuvo L J Tammela8, Anssi Auvinen3. 1. Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: tuomas.kilpelainen@hus.fi. 2. Department of Urology, Kanta-Häme Central Hospital, Hämeenlinna, Finland. 3. School of Health Sciences, University of Tampere, Tampere, Finland. 4. Finnish Cancer Registry, Helsinki, Finland. 5. School of Health Sciences, University of Tampere, Tampere, Finland; UKK Institute for Health Promotion Research, Tampere, Finland. 6. Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 7. Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland. 8. Department of Urology, University of Tampere, Tampere University Hospital, Tampere, Finland; Department of Urology, Tampere University Hospital, Tampere, Finland.
Abstract
PURPOSE: Screening for prostate cancer remains controversial, although ERSPC (European Randomized Study of Screening for Prostate Cancer) showed a 21% relative reduction in prostate cancer mortality. The Finnish Randomized Study of Screening for Prostate Cancer, which is the largest component of ERSPC, demonstrated a statistically nonsignificant 16% mortality benefit in a separate analysis. The purpose of this study was to estimate the degree of contamination in the control arm of the Finnish trial. MATERIALS AND METHODS:Altogether 48,295 and 31,872 men were randomized to the control and screening arms, respectively. The screening period was 1996 to 2007. The extent of prostate specific antigen testing was analyzed retrospectively using laboratory databases. The incidence of T1c prostate cancer (impalpable prostate cancer detected by elevated prostate specific antigen) was determined from the national Finnish Cancer Registry. RESULTS: Approximately 1.4% of men had undergone prostate specific antigen testing 1 to 3 years before randomization. By the first 4, 8 and 12 years of followup 18.1%, 47.7% and 62.7% of men in the control arm had undergone prostate specific antigen testing at least once and in the screening arm the proportions were 69.8%, 81.1% and 85.2%, respectively. The cumulative incidence of T1c prostate cancer was 6.1% in the screening arm and 4.5% in the control arm (RR 1.21, 95% CI 1.13-1.30). CONCLUSIONS: A large proportion of men in the control arm had undergone a prostate specific antigen test during the 15-year followup. Contamination is likely to dilute differences in prostate cancer mortality between the arms in the Finnish screening trial.
RCT Entities:
PURPOSE: Screening for prostate cancer remains controversial, although ERSPC (European Randomized Study of Screening for Prostate Cancer) showed a 21% relative reduction in prostate cancer mortality. The Finnish Randomized Study of Screening for Prostate Cancer, which is the largest component of ERSPC, demonstrated a statistically nonsignificant 16% mortality benefit in a separate analysis. The purpose of this study was to estimate the degree of contamination in the control arm of the Finnish trial. MATERIALS AND METHODS: Altogether 48,295 and 31,872 men were randomized to the control and screening arms, respectively. The screening period was 1996 to 2007. The extent of prostate specific antigen testing was analyzed retrospectively using laboratory databases. The incidence of T1c prostate cancer (impalpable prostate cancer detected by elevated prostate specific antigen) was determined from the national Finnish Cancer Registry. RESULTS: Approximately 1.4% of men had undergone prostate specific antigen testing 1 to 3 years before randomization. By the first 4, 8 and 12 years of followup 18.1%, 47.7% and 62.7% of men in the control arm had undergone prostate specific antigen testing at least once and in the screening arm the proportions were 69.8%, 81.1% and 85.2%, respectively. The cumulative incidence of T1c prostate cancer was 6.1% in the screening arm and 4.5% in the control arm (RR 1.21, 95% CI 1.13-1.30). CONCLUSIONS: A large proportion of men in the control arm had undergone a prostate specific antigen test during the 15-year followup. Contamination is likely to dilute differences in prostate cancer mortality between the arms in the Finnish screening trial.
Authors: Melissa Assel; Liisa Sjöblom; Teemu J Murtola; Kirsi Talala; Paula Kujala; Ulf-Håkan Stenman; Kimmo Taari; Anssi Auvinen; Andrew Vickers; Tapio Visakorpi; Teuvo L Tammela; Hans Lilja Journal: Eur Urol Focus Date: 2017-11-11
Authors: Eveline A M Heijnsdijk; Jan Adolfsson; Anssi Auvinen; Monique J Roobol; Jonas Hugosson; Harry J de Koning Journal: Eur Urol Date: 2019-04-26 Impact factor: 20.096
Authors: Anssi Auvinen; Antti Rannikko; Kimmo Taari; Paula Kujala; Tuomas Mirtti; Anu Kenttämies; Irina Rinta-Kiikka; Terho Lehtimäki; Niku Oksala; Kim Pettersson; Teuvo L Tammela Journal: Eur J Epidemiol Date: 2017-07-31 Impact factor: 8.082
Authors: Maria Frånlund; Marianne Månsson; Rebecka Arnsrud Godtman; Gunnar Aus; Erik Holmberg; Karin Stinesen Kollberg; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Hans Lilja; Jonas Hugosson Journal: J Urol Date: 2022-04-15 Impact factor: 7.600
Authors: Antti Rannikko; Mare Leht; Tuomas Mirtti; Anu Kenttämies; Teemu Tolonen; Irina Rinta-Kiikka; Tuomas P Kilpeläinen; Kari Natunen; Hans Lilja; Terho Lehtimäki; Jani Raitanen; Paula Kujala; Johanna Ronkainen; Mika Matikainen; Anssi Petas; Kimmo Taari; Teuvo Tammela; Anssi Auvinen Journal: BJU Int Date: 2022-01-08 Impact factor: 5.969